Therapeutics News and Research

RSS

First neurovascular unit opens at Krembil Neuroscience Centre

The first neurovascular unit (NVU) in Canada opened today at the Krembil Neuroscience Centre, Toronto Western Hospital, which is part of the University Health Network.

1 Dec 2011

Onconova uses BioClinica EDC, data management services to support clinical trials

BioClinica, Inc., a global provider of clinical trial management solutions, today announced that Onconova Therapeutics, Inc. has extended agreements using BioClinica Express electronic data capture (EDC) and data management services to support their clinical trials world-wide.

From Clario 1 Dec 2011

Neuropharmacology to publish Nutra Pharma's Alpha-Cobratoxin mechanism study on chronic pain

Nutra Pharma Corporation, a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the journal Neuropharmacology will be publishing a mechanism study on the use of Alpha-Cobratoxin, a component of cobra venom, as a treatment for pain.

1 Dec 2011

PTC, Roche announce licensing agreement for SMA programme

Roche, PTC Therapeutics, Inc. and the SMA Foundation, announced today a licensing agreement for PTC's Spinal Muscular Atrophy (SMA) programme.

30 Nov 2011

Enrollment complete in Alnylam's ALN-RSV01 Phase IIb study for RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has completed patient enrollment in its Phase IIb study with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection.

29 Nov 2011

New glycoconjugate vaccine prototype more effective than traditional vaccines

Brigham and Women's Hospital (BWH) researchers have created a vaccine that is more potent than traditional vaccines available today. The glycoconjugate vaccine prototype is 100 times more effective than traditional glycoconjugate vaccines. Their work is published in the December 2011 issue of Nature Medicine.

29 Nov 2011

New research institute at The University of Texas MD Anderson Cancer Center

Academic and government leaders announced today the establishment of a major new research institute at The University of Texas MD Anderson Cancer Center that will blend the best attributes of academic and industrial research to identify and validate new cancer targets, convert such scientific knowledge into new cancer drugs, and advance these novel agents into innovative clinical trials.

29 Nov 2011

Ferrer introduces citicoline oral solution medical food

Ferrer Therapeutics, the U.S. subsidiary of the international pharmaceutical group, Ferrer Grupo, is introducing CerAxon- Oral Solution to the U.S. market, the first and only oral solution medical food containing citicoline, a nutrient naturally produced by the body and found in the brain.

29 Nov 2011

Scientists identify cellular protein that plays central role in formation of new blood vessels

Scientists at the University of North Carolina at Chapel Hill School of Medicine have identified a cellular protein that plays a central role in the formation of new blood vessels.

29 Nov 2011

Researchers pinpoint cancer-fighting potential in bat plant

In a new study published this month in the Journal of the American Chemical Society, researchers with The University of Texas Health Science Center at San Antonio have pinpointed the cancer-fighting potential in the bat plant, or Tacca chantrieri.

23 Nov 2011

Targeting synthetic RNA to specific gene could help reduce severity of SMA

A team of University of Missouri researchers have found that targeting a synthetic molecule to a specific gene could help the severity of the disease Spinal Muscular Atrophy (SMA) - the leading genetic cause of infantile death in the world.

22 Nov 2011

Despite market constraints, the drug market for key hospital-treated infections will increase: Report

Decision Resources finds that the drug market for key hospital-treated infections that are of high interest to drug developers—most notably nosocomial pneumonia, bloodstream infections, skin and skin structure/surgical site infections and urinary tract infections—will increase from $3.3 billion in 2010 to just over $4 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

21 Nov 2011

Akebia commences dosing in AKB-9778 Phase 1 study for diabetic macular edema and retinopathy

Akebia Therapeutics, Inc., a small molecule discovery and development company focused on anemia and vascular disorders, today announced that it has dosed the first subjects in a first-in-man Phase 1 study of AKB-9778, a first-in-class human protein tyrosine phosphatase beta (HPTPβ) inhibitor in development for diabetic macular edema (DME) and diabetic retinopathy (DR).

21 Nov 2011

Consistent data from three studies support plans for rindopepimut with ACT IV Phase 3 study

Celldex Therapeutics, Inc. today announced the presentation of mature overall survival (OS) data for ACT III, a multi-center, single arm, Phase 2 clinical trial of rindopepimut (CDX-110) in patients with newly diagnosed EGFRvIII-positive glioblastoma (GB).

21 Nov 2011

Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).

21 Nov 2011

Adeona to develop and commercialize DNA-based therapeutic for PAH using Intrexon technology

Adeona Pharmaceuticals, Inc., and the Human Therapeutics Division of Intrexon Corporation, announced today the formation of a global exclusive channel collaboration through which Adeona intends to develop and commercialize a DNA-based therapeutic using Intrexon's UltraVector platform and RheoSwitch Therapeutic System for the treatment of pulmonary arterial hypertension (PAH).

21 Nov 2011

CTI receives U.S. Patent Allowance for GlycoPolymer technology

Cell Therapeutics, Inc. (CTI) announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application directed to increasing the plasma half-life of therapeutic proteins and peptides by recombinantly conjugating them to a novel, non-immunogenic peptide repeat sequence.

21 Nov 2011

Shire, Shionogi enter agreement to co-develop and co-commercialize ADHD medicines in Japan

Shire plc, the global specialty biopharmaceutical company, announces that it has entered into an agreement with Shionogi & Co. Ltd. of Japan to co-develop and co-commercialize certain of Shire's Attention Deficit Hyperactivity Disorder (ADHD) medicines in Japan.

19 Nov 2011

Tikcro reports net loss of $1.0 million for third quarter 2011

Tikcro Technologies Ltd. today reported results for the third quarter and nine months ended September 30, 2011.

18 Nov 2011

Dendrimers can capture circulating tumor cells in blood by biomimicry

The removal of rare tumor cells circulating in the blood might be possible with the use of biomolecules bound to dendrimers, highly branched synthetic polymers, which could efficiently sift and capture the diseased cells, according to new research at the University of Illinois at Chicago.

18 Nov 2011

Therapeutics News and Research

First neurovascular unit opens at Krembil Neuroscience Centre

Onconova uses BioClinica EDC, data management services to support clinical trials

Neuropharmacology to publish Nutra Pharma's Alpha-Cobratoxin mechanism study on chronic pain

PTC, Roche announce licensing agreement for SMA programme

Enrollment complete in Alnylam's ALN-RSV01 Phase IIb study for RSV infection

New glycoconjugate vaccine prototype more effective than traditional vaccines

New research institute at The University of Texas MD Anderson Cancer Center

Ferrer introduces citicoline oral solution medical food

Scientists identify cellular protein that plays central role in formation of new blood vessels

Researchers pinpoint cancer-fighting potential in bat plant

Targeting synthetic RNA to specific gene could help reduce severity of SMA

Despite market constraints, the drug market for key hospital-treated infections will increase: Report

Akebia commences dosing in AKB-9778 Phase 1 study for diabetic macular edema and retinopathy

Consistent data from three studies support plans for rindopepimut with ACT IV Phase 3 study

Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis

Adeona to develop and commercialize DNA-based therapeutic for PAH using Intrexon technology

CTI receives U.S. Patent Allowance for GlycoPolymer technology

Shire, Shionogi enter agreement to co-develop and co-commercialize ADHD medicines in Japan

Tikcro reports net loss of $1.0 million for third quarter 2011

Dendrimers can capture circulating tumor cells in blood by biomimicry

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News